While androgen deprivation therapy (ADT) is initially effective in most men with advanced PC, the emergence of castration-resistant prostate cancer (CRPC) and resistance to androgen receptor (AR) signaling inhibitors (ARSIs) develops in almost all patients2,3. This evidence concerns the gene AR and pachyonychia congenita.